PEPG

PepGenC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$3.40

+134.5% vs current

Most likely

Base case

45%

Probability

Target price

$1.40

-3.4% vs current

B-

Bear case

30%

Probability

Target price

$0.60

-58.6% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

This is best framed as a cautious monitoring biotech setup, not a clean bullish thesis. Primary sources support two things at once: PepGen still has an active ex-U.S. trial, runway, and a defined 10 mg/kg readout path, but the U.S. partial hold and only modest disclosed 5 mg/kg efficacy keep conviction capped. Direct same-indication peers now look clearer, but the deterministic prior is still negative and that fits the current risk-reward until the next regulatory or clinical proof point arrives.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-09-30catalystFDA partial clinical hold resolution remains the key swing factorHigh impact

The main near-term overhang is the FDA partial clinical hold on FREEDOM2 tied to preclinical pharmacology and toxicology questions; PepGen said no U.S. patients were enrolled, ex-U.S. dosing continues, and the company is submitting additional analyses to address FDA questions [#IR-2026-03-04][#10-K-2026-03-04].

2026-10-15eventFREEDOM2 10 mg/kg cohort readout in 2H 2026High impact

PepGen said the 10 mg/kg FREEDOM2 cohort is actively dosing, was more than halfway enrolled as of March 30, 2026, and remains on track for a second-half 2026 data readout after the 5 mg/kg cohort showed favorable safety with mixed but directionally positive biomarker/functional signals [#8-K-2026-03-30].

2027-07-01catalystRunway into 2H 2027 limits immediate financing pressureHigh impact

PepGen reported $148.5 million of cash, cash equivalents, and marketable securities at December 31, 2025 and guided that this should fund currently planned operations into the second half of 2027, which helps preserve time for FREEDOM2 and OLE execution before another capital raise becomes unavoidable [#10-K-2026-03-04].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology